High Quality Imatinib with Good Price (CAS 152459-95-5)

Product Description
High Quality Imatinib with Good Price (CAS 152459-95-5)

  • Model NO.: Imatinib
  • Customized: Non-Customized
  • Suitable for: Adult
  • Purity: >99%
  • Market: Worldwide
  • Transport Package: 10g/100g/1000g
  • Origin: Made in China
  • Powder: Yes
  • Certification: ISO 9001
  • State: Solid
  • Sample: Free
  • Trademark: NJBN STEROID
  • Specification: 152459-95-5
  • HS Code: 3001909010
Product Description
Chronic Myelogenous Leukemia And Malignancies Treatment 152459-95-5 Imatin

————————————————-

Imatinib

Product Name Imatinib
Synonyms IMA-3;IMATINIB;IMATINIB-D3;AKOS 91378;IMATINIB 99+%;Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-;Imatinib Mesilate;4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate
CAS 152459-95-5
MF C29H31N7O
MW 493.6
Chemical Properties Orange Solid
Usage Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively. Imatinib also known as Gleevec, Glivec, CGP-57148B, STI-571 & Imatinib
antineoplastic
atypical antipsychotic
Imatinib impurity

————————————————-

Description of Imatinib

1.Imatinib (INN), marketed by Novartis as Gleevec (Canada, South Africa and the USA) or Glivec (Australia, Europe and Latin America), investigational name STI-571, is a tyrosine-kinase inhibitor used in the treatment of multiple cancers, most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML).

2.Imatinib kills cancer cells by turning off tyrosine kinases. In order to survive, cells need signaling through proteins (signal cascade) to keep them alive. Some of the proteins in this cascade use a phosphate group as an “on” switch. This phosphate group is added by a tyrosine kinase enzyme. In healthy cells, these tyrosine kinase enzymes are turned on and off as needed. In Ph-positive CML cells, one tyrosine kinase enzyme, BCR-Abl, is stuck on the “on” position, and keeps adding phosphate groups. Imatinib blocks this BCR-Abl enzyme, and stops it from adding phosphate groups. As a result, these cells stop growing, and even die by a process of cell death (apoptosis). Because the BCR-Abl tyrosine kinase enzyme exists only in cancer cells and not in healthy cells, imatinib works as a form of targeted therapy-only cancer cells are killed through the drug’s action. In this regard, imatinib was one of the first cancer therapies to show the potential for such targeted action, and is often cited as a paradigm for research in cancer therapeutics.

3.Due in large part to the development of Gleevec and related drugs having a similar mechanism of action, the five year survival rate for people with chronic myeloid leukemia nearly doubled from 31% in 1993 (before Gleevec’s 2001 FDA approval) to 59% for those diagnosed between 2003 and 2009.Compared to older drugs imatinib has a relatively benign side effect profile, allowing many patients to live a normal lifestyle. Median survival for imatinib-treated people with gastrointestinal stromal tumors (GIST) is nearly 5 years compared to 9 to 20 months in the pre-imatinib-era.

————————————————-

Medical uses
Imatinib is used to treat chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies.

Author: chemicals

Here is chemical sourse

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s